NCT02934555

Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Beth Israel Deaconess Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To study the effects of ubiquinol as a "metabolic resuscitator" in post-cardiac arrest.

Detailed description

Cardiac arrest (CA) occurs in more than 400,000 patients in the United States each year with an estimated mortality of greater than 90%. The majority of patients who are resuscitated from CA will succumb to the neurologic morbidity associated with the post-CA syndrome and ischemic-reperfusion injury. Currently, there are no pharmacologic agents known to offer survival benefit or to prevent devastating neurologic injury in post-CA patients. A potential therapeutic target following ischemia-reperfusion injury is mitochondrial function in the injured cell and/or reduction of oxygen free radicals. Coenzyme Q10 (CoQ10) is an essential mitochondrial co-factor and free radical scavenger that has been proposed as a neuroprotective agent in various neurodegenerative disorders as well as a cardioprotective agent. CoQ10 have furthermore shown exciting preliminary results as a potential therapy in post-CA. In order to test the effects of ubiquinol as a "metabolic resuscitator" in post-CA patients and to provide additional preliminary data for a large-scale clinical trial, the investigators are conducting a randomized, double-blind, place-controlled trial of ubiquinol in post-CA patients.

Conditions

• Cardiac Arrest

Interventions

Type	Name	Description
DRUG	Ubiquinol	300 mg Ubiquinol (3 mL liquid Ubiquinol).
DIETARY_SUPPLEMENT	Ensure	50 mL Ensure

Timeline

• Start date: 2016-03-01
• Primary completion: 2019-05-25
• Completion: 2019-06-02
• First posted: 2016-10-17
• Last updated: 2021-02-15
• Results posted: 2021-02-15

Locations

1 site across 1 country: United States